Enanta Pharma (ENTA) Misses Q4 EPS by 20c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.36), $0.20 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.61 million versus the consensus estimate of $17.99 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• TMCR raises $165M to acquire additional Mesabi iron ore royalty